Clinical trials: Irritable Bowel Syndrome With Constipation
Irritable Bowel Syndrome
Prevalence of Intestinal Parasitic Infections in Patients With Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is common medical disorder and represent a group of diseases of the gastrointestinal tract that is characterized by chronic abdominal pain , bloating , passage of mucus or straining with bowel…
- Trial name
- NCT05830370
- Where
- Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sohag University
Irritable Bowel Syndrome-IBS
Effect of Different Dietary Therapies on Intestinal Barrier Integrity in Patients With Irritable Bowel Syndrome
This study aims to evaluate the effects of different dietary treatments on intestinal integrity in female subjects aged 19-50 years previously diagnosed with constipation-predominant irritable bowel syndrome (IBS).
- Trial name
- NCT06421922
- Testing
- Group 1 received a regular constipation diet, Group 2 received a constipation diet rich in soluble fiber, Group 3 received a constipation diet supplemented with probiotic yogurt.
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Gulhane Training and Research Hospital
Constipation-Predominant Irritable Bowel Syndrome
Randomized Trial of Mosapride Versus Placebo in the Treatment of Constipation-Predominant Irritable Bowel Syndrome
The purpose of this study is to determine whether Mosapride, an agent which acts on serotonin receptors in the gastrointestinal tract, is effective in the treatment of constipation-predominant irritable bowel syndrome (C-IBS).
- Trial name
- NCT00742872
- Testing
- Mosapride Citrate
- Where
- Lebanon
- Volunteers
- 41 people
- Sponsor
- American University of Beirut Medical Center
Irritable Bowel Syndrome
Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.
- Trial name
- NCT00813098
- Testing
- LX1031 High Dose, LX1031 Low Dose
- Where
- 36 sites in United States
- Volunteers
- 155 people
- Sponsor
- Lexicon Pharmaceuticals
Women With IBS-C
A Single-centre, Randomised, Double-blind, Controlled, Parallel-group Study to Evaluate the Effect of a Fermented Dairy Product on Abdominal Distension, Digestive Symptoms and Rectal Sensitivity in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
The purpose of this study is to evaluate the effect of a commercially available fermented dairy product containing probiotics (4 weeks, twice a day) on abdominal distension in IBS patients with constipation (IBS-C).
- Trial name
- NCT01097993
- Testing
- 1-fermented dairy product, 2- milk-based non-fermented dairy product (control product)
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Danone Global Research & Innovation Center
Irritable Bowel Syndrome
The Effects of Prucalopride in Patients With Constipation Predominant Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is very common functional gastrointestinal disorder in daily gastrointestinal practice. Its etiology is multifactorial and incompletely understood.
- Trial name
- NCT04757493
- Testing
- Prucalopride 2mg
- Where
- Bangladesh
- Volunteers
- 160 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Irritable Bowel Syndrome
Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation
Patients suffering from Irritable Bowel Syndrome with predominant constipation will be provided with the study medication. The study medication will be evaluated for its efficacy in relieving the symptoms
- Trial name
- NCT01027260
- Testing
- Itopride HCI 50 mg, Itopride HCI 100 mg
- Where
- 4 sites in Pakistan
- Volunteers
- 268 people
- Sponsor
- Abbott
Irritable Bowel Syndrome With Constipation (IBS-C)
A Study of the Effect of SYN-010 on Subjects With IBS-C
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared with Placebo on Breath Methane Production in Breath Methane-Positive Subjects with…
- Trial name
- NCT02495623
- Testing
- SYN-010 21 mg, SYN-010 42 mg
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Theriva Biologics, Inc.
Bloating, Rifaximin
Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders
This randomized, double-blind, placebo-controlled trial will evaluate the effects of a 14-day course of rifaximin on bloating symptoms, gut microbiota, microbial metabolites, and intestinal gases in adults with Rome V irritable…
- Conditions
- Bloating, Rifaximin, Functional Bowel Disorder, Irritable Bowel Syndrome
- Trial name
- NCT07522255
- Testing
- Rifaximin (drug)
- Where
- Thailand
- Volunteers
- 78 people
- Sponsor
- Mahidol University
Irritable Bowel Syndrome With Constipation
A Study of Virtual Reality and Linaclotide for IBS-C
The purpose of this study is to determine if adult patients with IBS-C will report an overall greater improvement in IBS symptoms and quality of life when treated with a combination of linaclotide (standard of care medication)…
- Trial name
- IBSC-VR (NCT05796388)
- Testing
- Virtual Reality
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome, Constipation
Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation
This trial is to investigate efficacy and safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation. The difference of responder rate between test group (10, 20 and 40mg) and placebo will be evaluated.
- Trial name
- YKP (NCT02082457)
- Testing
- YKP10811 5mg, YKP10811 20mg
- Where
- South Korea
- Volunteers
- 273 people
- Sponsor
- SK Chemicals Co., Ltd.
Irritable Bowel Syndrome With Constipation
Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.
- Trial name
- NCT00460811
- Testing
- Linaclotide Acetate
- Where
- 85 sites in United States, Canada
- Volunteers
- 420 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Constipation-Predominant Irritable Bowel Syndrome
Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
The main purpose of this study is to evaluate the long-term safety and tolerability of renzapride at a dose of 4 mg taken once daily for 12 months in women with constipation-predominant irritable bowel syndrome (IBS-C).
- Trial name
- NCT00607971
- Testing
- Renzapride
- Where
- 126 sites in United States
- Volunteers
- 939 people
- Sponsor
- Alizyme
IBS
The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS)
This study objective is to assess the short and long term effects of partially hydrolyzed guar gum (PHGG) administration on clinical symptoms of IBS and quality of life of these patients.
- Trial name
- NCT01779765
- Testing
- PHGG, Maltodextrin
- Where
- Israel
- Volunteers
- 130 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Non-Constipation Irritable Bowel Syndrome
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
- Trial name
- TARGET 1 (NCT00731679)
- Testing
- Rifaximin
- Where
- 96 sites in United States, Canada
- Volunteers
- 623 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome With Constipation
Home Transcutaneous Electrical Acustimulation (TEA)
This study will assess the efficacy of two active treatments with TEA and a chemical neuromodulator (escitalopram aka Lexapro) versus a sham comparator or control group on abdominal pain.
- Trial name
- Home-TEA (NCT05519683)
- Testing
- TEA, Lexapro
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Michigan
Constipation, Constipation by Outlet Obstruction
The Impact of Aerobic Interval and Inspiratory Muscle Training On Patient Reported Outcome Scores In Individuals With Chronic Constipation
The primary aim of this study will be to determine if the addition of aerobic interval and inspiratory muscle training (IMT) targeted at improving cardiopulmonary-based measures will further improve patient satisfaction scores in…
- Conditions
- Constipation, Constipation by Outlet Obstruction, Constipation-predominant Irritable Bowel Syndrome, Constipation - Functional
- Trial name
- NCT05321953
- Testing
- Standard Physical Therapy Care, Aerobic and Inspiratory Muscle Training
- Where
- United States
- Sponsor
- University of Miami
Irritable Bowel Syndrome, Irritable Bowel Syndrome - Constipation
Efficacy of Chatbot for Irritable Bowel Syndrome (IBS) Patients
The goal of this clinical trial is to evaluate the efficacy of an automated chatbot system in improving quality of life, reducing depression and anxiety, and decreasing visceral sensitivity in patients with Irritable Bowel…
- Conditions
- Irritable Bowel Syndrome, Irritable Bowel Syndrome - Constipation, Irritable Bowel Syndrome - Diarrhoea, Irritable Bowel Syndrome - Mixed
- Trial name
- IrBiS (NCT06837064)
- Testing
- Chatbot supporting system
- Where
- Russia
- Volunteers
- 54 people
- Sponsor
- Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
Chronic Idiopathic Constipation
SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation
This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose ranging study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) effects of SP-304 in patients with chronic…
- Trial name
- CIC (NCT01053962)
- Testing
- SP-304 0.3 mg, SP-304 1.0 mg, SP-304 3.0 mg
- Where
- 14 sites in United States
- Volunteers
- 84 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome With Constipation
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation
The purpose of this study is to evaluate the safety and efficacy of linaclotide for the treatment of Irritable Bowel syndrome with Constipation (IBS-C), in children age 7-17 years.
- Trial name
- LIN-MD-63 (NCT02559817)
- Testing
- Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C
- Where
- 48 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Forest Laboratories